Back

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Beau Van Driel

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects
Doctor C. Ho (Boston, US)
Slides Video
Presentation thumbnail
Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study
Doctor P. Garcia-Pavia (Majadahonda, ES)
Abstract Slides Video
Presentation thumbnail
Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM
Doctor C. Coats (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis
Doctor A. Masri (Portland, US)
Abstract Slides Video

Access the full session

Session thumbnail
Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Session
Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects
thumbnail
Congress Session
Hypertrophic cardiomyopathy: from gene to treatment
thumbnail
Congress Presentation
A Phase 2 Trial of Trientine for Hypertrophic Cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources